Streetbeat News

Analyst Ratings

TKO

Guggenheim analyst Curry Baker maintains a Buy rating on TKO Group Holdings (NYSE:TKO) but has lowered the price target from $130 to $126.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:49 pm

AAPL

B of A Securities analyst Wamsi Mohan has reiterated a Neutral rating on Apple (NASDAQ:AAPL) and maintained a price target of $208.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:48 pm

SEEL

Guggenheim analyst Yatin Suneja has downgraded Seelos Therapeutics (NASDAQ:SEEL) from Buy to Neutral.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:47 pm

ORCL

Guggenheim analyst John Difucci has reiterated a 'Buy' rating on Oracle (NYSE:ORCL) and maintained a price target of $150.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:45 pm

WMG

Jefferies analyst Andrew Uerkwitz maintains a Buy rating on Warner Music Group (NASDAQ:WMG) but lowers the price target from $37 to $35.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:45 pm

PRU

Prudential Financial Inc.'s (NYSE:PRU) stock price is currently at $96.87, after a 0.10% drop. However, the stock has risen by 3.34% over the past month and by 10.91% over the past year. The company's P/E ratio is lower than the aggregate P/E of the Insurance industry, which could indicate that the stock is undervalued or that shareholders do not expect future growth.

Portfolio Pulse from Benzinga Insights

September 22, 2023 | 3:45 pm

NKE

Guggenheim analyst Robert Drbul has reiterated a 'Buy' rating on Nike (NYSE:NKE) and maintained a price target of $135.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:44 pm

MCW

Guggenheim analyst John Heinbockel has reiterated a 'Buy' rating on Mister Car Wash (NYSE:MCW) and maintained a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:42 pm

IMVT

Guggenheim analyst Yatin Suneja has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:41 pm

CSBR

Roth MKM analyst Scott Henry maintains a Buy rating on Champions Oncology (NASDAQ:CSBR) but lowers the price target from $9 to $7.5.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:40 pm